Rodríguez-Fernández Laura F, Bernaschina-Bobadilla Claudio P
Surgery, Ponce Health Sciences University, Ponce, PRI.
Urology, St. Luke's Episcopal Hospital, Ponce, PRI.
Cureus. 2023 Apr 27;15(4):e38193. doi: 10.7759/cureus.38193. eCollection 2023 Apr.
UroLift is a novel, minimally invasive surgical technique used to treat bladder outlet obstruction due to benign prostatic hyperplasia (BPH). UroLift was granted US FDA approval in 2013, and so far, it has gained acceptance and popularity worldwide. In this case report, we present a 69-year-old male patient that developed a pelvic hematoma with subacute clinical manifestations two months following UroLift. The patient was managed conservatively, resulting in the complete resolution of the hematoma. As more surgeons are trained, and the caseload increases, we expect to see more complications related to this novel technique. Surgeons should be aware of this procedure's potential short- and long-term complications.
UroLift是一种用于治疗良性前列腺增生（BPH）所致膀胱出口梗阻的新型微创手术技术。UroLift于2013年获得美国食品药品监督管理局（FDA）批准，迄今为止，它已在全球范围内得到认可并广泛应用。在本病例报告中，我们介绍了一名69岁男性患者，其在接受UroLift手术两个月后出现了具有亚急性临床表现的盆腔血肿。该患者接受了保守治疗，血肿得以完全消退。随着越来越多的外科医生接受培训以及病例数量的增加，我们预计会看到与这种新技术相关的更多并发症。外科医生应了解该手术潜在的短期和长期并发症。
